Immediate Impact
5 from Science/Nature 57 standout
Citing Papers
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
2025 Standout
The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy
2025 Standout
Works of Piers Patten being referenced
CELESTIAL-TNCLL: An ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-naïve (TN) CLL.
2024
Interaction with Vascular Endothelium Enhances Survival in Primary Chronic Lymphocytic Leukemia Cells via NF-κB Activation and De novo Gene Transcription
2010
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Piers Patten | 838 | 579 | 303 | 483 | 69 | 1.1k | |
| Jerzy Z. Błoński | 770 | 625 | 280 | 393 | 72 | 1.2k | |
| Ludger Sellmann | 667 | 414 | 266 | 522 | 31 | 1.1k | |
| Yair Herishanu | 418 | 441 | 383 | 403 | 87 | 1.1k | |
| Robert Foà | 885 | 616 | 254 | 748 | 57 | 1.4k | |
| John N. Allan | 745 | 674 | 316 | 304 | 93 | 1.1k | |
| Elisa ten Hacken | 657 | 341 | 202 | 413 | 34 | 920 | |
| Mehrdad Mobasher | 877 | 652 | 419 | 379 | 39 | 1.3k | |
| Andrea G.S. Buggins | 459 | 246 | 249 | 616 | 32 | 1.1k | |
| Fabienne McClanahan | 683 | 445 | 506 | 542 | 34 | 1.2k | |
| Evgeny Arons | 756 | 486 | 240 | 438 | 45 | 990 |
All Works
Login with ORCID to disown or claim papers
Loading papers...